SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

09 Feb 2023 Evaluate
The revenue zoomed 22.72% to Rs. 1488.04 millions for the quarter ended December 2022 as compared to Rs. 1212.54 millions during the corresponding quarter last year.Profit after Tax for the quarter ended December 2022 saw a decline of -52.14% from Rs. 105.06 millions to Rs. 50.28  millions.Operating Profit reported a sharp decline to 204.80 millions from 294.10 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1488.04 1212.54 22.72 3726.26 4590.98 -18.84 5198.74 5631.78 -7.69
Other Income 22.14 21.30 3.94 36.29 46.29 -21.60 51.98 34.53 50.54
PBIDT 204.80 294.10 -30.36 350.86 1235.43 -71.60 1196.83 1245.63 -3.92
Interest 59.36 47.52 24.92 160.29 145.35 10.28 188.75 111.62 69.10
PBDT 145.44 246.58 -41.02 190.57 1090.08 -82.52 1008.08 1134.01 -11.10
Depreciation 81.25 80.96 0.36 241.51 241.81 -0.12 321.52 222.82 44.30
PBT 64.19 165.62 -61.24 -50.94 848.27 -106.01 686.56 911.19 -24.65
TAX 13.91 60.56 -77.03 -11.03 258.51 -104.27 6.18 301.55 -97.95
Deferred Tax 14.50 25.56 -43.27 -10.44 78.51 -113.30 -143.02 141.09 -201.37
PAT 50.28 105.06 -52.14 -39.91 589.76 -106.77 680.38 609.64 11.60
Equity 84.65 84.65 0.00 84.65 84.65 0.00 84.65 84.65 0.00
PBIDTM(%) 13.76 24.25 -43.26 9.42 26.91 -65.01 23.02 22.12 4.09

SMS Pharmaceuticals Share Price

414.90 -5.70 (-1.36%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×